Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
Shankar SivaAlexander V LouieAndrew WarnerAlexander MuacevicSenthilkumar GandhidasanLee PonskyRodney EllisIrving KaplanAnand MahadevanWilliam ChuAnand SwaminathHiroshi OnishiBin TehRohann J CorreaSimon S LoMichael StaehlerPublished in: Cancer (2017)
SABR is well tolerated and locally effective for treating patients who have primary renal cell carcinoma and has an acceptable impact on renal function. An interesting observation is that patients who receive single-fraction SABR appear to be less likely to progress distantly or to die of cancer. Cancer 2018;124:934-42. © 2017 American Cancer Society.
Keyphrases
- papillary thyroid
- renal cell carcinoma
- squamous cell
- end stage renal disease
- chronic kidney disease
- early stage
- ejection fraction
- small cell lung cancer
- radiation therapy
- lymph node metastasis
- newly diagnosed
- brain metastases
- childhood cancer
- squamous cell carcinoma
- radiation induced
- prognostic factors
- young adults
- patient reported